Work

A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.6_suppl.tps708

Authors: Pavlos Msaouel, Peter F. Thall, Ying Yuan, Isan Chen, Nizar M. Tannir

Institutions: The University of Texas MD Anderson Cancer Center, Mirati Therapeutics (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2792494085

Cites:

Cited by: 4

Related to: 10